Loading clinical trials...
Loading clinical trials...
Zortress (everolimus), the 40-O-(2-hydroxyethyl)-derivative of rapamycin, is an mTOR inhibitor approved for rejection prophylaxis in kidney transplant recipients. mTOR inhibition may favorably impact ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of California, San Francisco
Collaborators
NCT07415421 · Hyperparathyroidism, Kidney Transplantation Recipients
NCT07209917 · Cervical Cancer, Human Papillomavirus (HPV) Infection, and more
NCT07392372 · HIV -1 Infection
NCT06853314 · HIV Infections, Alcohol Use Disorder, and more
NCT06472973 · Alcohol Associated Liver Disease, Liver Transplantation
University of California, San Francisco
San Francisco, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions